{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:40:04Z","timestamp":1793893204619,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bbrep.2024.101741","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T13:24:25Z","timestamp":1717075465000},"page":"101741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Lili","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-031X","authenticated-orcid":false,"given":"Xuelong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7688-5955","authenticated-orcid":false,"given":"Luo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8124-7387","authenticated-orcid":false,"given":"Xiushan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.bbrep.2024.101741_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101741_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"4","key":"10.1016\/j.bbrep.2024.101741_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"9 Pt 2","key":"10.1016\/j.bbrep.2024.101741_bib4","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/S1051-0443(07)61788-6","article-title":"Role of liver transplantation in the management of hepatocellular carcinoma","volume":"13","author":"Patt","year":"2002","journal-title":"J. Vasc. Intervent. Radiol."},{"issue":"4","key":"10.1016\/j.bbrep.2024.101741_bib5","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrep.2024.101741_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101946","article-title":"Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.bbrep.2024.101741_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"10126","key":"10.1016\/j.bbrep.2024.101741_bib8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbrep.2024.101741_bib9","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol. Ther."},{"issue":"10064","key":"10.1016\/j.bbrep.2024.101741_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bbrep.2024.101741_bib11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.bbrep.2024.101741_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2015.06.001","article-title":"Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study","volume":"63","author":"Cheng","year":"2015","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101741_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41598-020-79524-3","article-title":"Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells","volume":"11","author":"Meng","year":"2021","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.bbrep.2024.101741_bib14","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbrep.2024.101741_bib15","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5501","article-title":"Bispecific GPC3\/PD-1 CAR-T cells for the treatment of HCC","volume":"62","author":"Li","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bbrep.2024.101741_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1499-3872(15)60349-6","article-title":"Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation","volume":"14","author":"Cui","year":"2015","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101741_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1039\/C8BM01016A","article-title":"An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis","volume":"7","author":"Zhang","year":"2018","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101741_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.bbrep.2024.101741_bib19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/modpathol.3800436","article-title":"The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma","volume":"18","author":"Yamauchi","year":"2005","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.bbrep.2024.101741_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016","journal-title":"J. Hepatol."},{"issue":"410","key":"10.1016\/j.bbrep.2024.101741_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.bbrep.2024.101741_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020271","article-title":"Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials","volume":"13","author":"Rochigneux","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrep.2024.101741_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: a new immunotherapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.bbrep.2024.101741_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21886","article-title":"Enhanced infection efficiency and cytotoxicity mediated by vpx-containing lentivirus in chimeric antigen receptor macrophage (CAR-M)","volume":"9","author":"Gao","year":"2023","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.bbrep.2024.101741_bib25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D Aloia","year":"2018","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.bbrep.2024.101741_bib26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.bbrep.2024.101741_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cmi.12580","article-title":"Macrophages: sentinels and regulators of the immune system","volume":"18","author":"Franken","year":"2016","journal-title":"Cell Microbiol."},{"issue":"1","key":"10.1016\/j.bbrep.2024.101741_bib28","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41467-018-04985-0","article-title":"Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vacuolar pathway","volume":"9","author":"Tang-Huau","year":"2018","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bbrep.2024.101741_bib29","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.4049\/jimmunol.181.9.5829","article-title":"Macrophages as APC and the dendritic cell myth","volume":"181","author":"Hume","year":"2008","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bbrep.2024.101741_bib30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/d41573-020-00053-9","article-title":"Macrophages get a CAR","volume":"19","author":"Villanueva","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbrep.2024.101741_bib31","article-title":"MitoQ protects ovarian organoids against oxidative stress during oogenesis and folliculogenesis in vitro","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2024.101741_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121213","article-title":"Generation of offspring-producing 3D ovarian organoids derived from female germline stem cells and their application in toxicological detection","volume":"279","author":"Li","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrep.2024.101741_bib33","article-title":"DNA origami assembled spheroid for evaluating cytotoxicity and infiltration of chimeric antigen receptor macrophage (CAR-M)","author":"Liu","year":"2023","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.bbrep.2024.101741_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824001055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824001055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T11:25:49Z","timestamp":1725189949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580824001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"alternative-id":["S2405580824001055"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101741","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101741"}}